ATE348099T1 - Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden - Google Patents

Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden

Info

Publication number
ATE348099T1
ATE348099T1 AT02714914T AT02714914T ATE348099T1 AT E348099 T1 ATE348099 T1 AT E348099T1 AT 02714914 T AT02714914 T AT 02714914T AT 02714914 T AT02714914 T AT 02714914T AT E348099 T1 ATE348099 T1 AT E348099T1
Authority
AT
Austria
Prior art keywords
disorders
dopamine
compounds
urea derivatives
receptors
Prior art date
Application number
AT02714914T
Other languages
English (en)
Inventor
James A Hendrix
Joseph T Strupczewski
Kenneth J Bordeau
Sarah Brooks
Horst Hemmerle
Matthias Urmann
Xu-Yang Zhao
Paul Justin Mueller
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0117950.6A external-priority patent/GB0117950D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE348099T1 publication Critical patent/ATE348099T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02714914T 2001-02-16 2002-02-15 Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden ATE348099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26965401P 2001-02-16 2001-02-16
GBGB0117950.6A GB0117950D0 (en) 2001-02-16 2001-07-23 Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands

Publications (1)

Publication Number Publication Date
ATE348099T1 true ATE348099T1 (de) 2007-01-15

Family

ID=26246345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714914T ATE348099T1 (de) 2001-02-16 2002-02-15 Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden

Country Status (10)

Country Link
EP (1) EP1392676B1 (de)
JP (1) JP4497814B2 (de)
AT (1) ATE348099T1 (de)
CA (1) CA2438316A1 (de)
DE (1) DE60216753T2 (de)
DK (1) DK1392676T3 (de)
ES (1) ES2275853T3 (de)
IL (1) IL157363A0 (de)
MX (1) MXPA03006843A (de)
WO (1) WO2002066468A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298627T3 (es) * 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
DE102004021637A1 (de) * 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
US20080275028A1 (en) * 2004-07-20 2008-11-06 Giovanni Gaviraghi Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2523731B1 (de) 2010-01-14 2018-10-24 Novartis AG Verwendung eines adrenal hormones modifizierenden wirkstoff
CN105367565B (zh) * 2014-08-20 2018-10-02 上海医药工业研究院 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用
EP3495363B1 (de) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Stickstoffhaltige kondensierte ringverbindungen mit antagonistischer dopamin-d3-rezeptor-wirkung
US12319659B2 (en) 2017-02-24 2025-06-03 Shenzhen Linglan Bio-Pharmaceutical Technology Co., Ltd Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CA3089498A1 (en) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94151A (en) * 1989-04-22 1995-08-31 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
EP0955296A3 (de) * 1989-04-22 2000-01-19 American Home Products Corporation Tertiäre alkyl funktionalisierte Piperazin-Derivate
DK181190D0 (da) * 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
DE69618050T2 (de) * 1995-03-17 2002-07-11 Aventis Pharmaceuticals Inc., Cincinnati Substituierte Benzylthienylpiperazine, ihre Anwendung als Arzneimittel und Verfahren für ihre Herstellung
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
IT1282705B1 (it) * 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US5703235A (en) * 1996-03-21 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU771199B2 (en) * 1999-01-08 2004-03-18 Neurogen Corporation 1-phenyl-4-(1-(2-aryl)cyclopropyl) methylpiperazines: dopamine receptor ligands
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
CA2375851A1 (en) * 1999-06-14 2000-12-21 Neurogen Corporation 1-azatricyclic-4-benzylpiperazines

Also Published As

Publication number Publication date
IL157363A0 (en) 2004-02-19
CA2438316A1 (en) 2002-08-29
JP4497814B2 (ja) 2010-07-07
WO2002066468A3 (en) 2002-10-17
DE60216753D1 (de) 2007-01-25
EP1392676B1 (de) 2006-12-13
MXPA03006843A (es) 2003-11-13
DK1392676T3 (da) 2007-04-10
ES2275853T3 (es) 2007-06-16
DE60216753T2 (de) 2008-01-03
WO2002066468A2 (en) 2002-08-29
EP1392676A2 (de) 2004-03-03
JP2004518744A (ja) 2004-06-24

Similar Documents

Publication Publication Date Title
ES2253526T3 (es) Derivados de carbonilo sustituidos heterociclicos y su uso como ligandos de receptores d3 de dopamina.
WO2002066469A3 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
CO5370677A1 (es) Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
DE60216753D1 (de) Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
ATE451368T1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
DE602004025244D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
EA200702135A1 (ru) Лечение болезни паркинсона, обструктивного синдрома апноэ во сне, слабоумия с тельцами льюи, сосудистой деменции с помощью не содержащих имидазола алкиламиновых лигандов гистаминовых н3-рецепторов
BR0307504A (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
CO5390077A1 (es) Nuevos derivados heterociclicos de urea y su uso como ligantes receptores d3 de dopamina
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
BR0208241A (pt) Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto
DE60238717D1 (de) Derivate und pharmazeutische zusammensetzungen von n-hydroxyalkyltetramethyl cyclo propan carboxamid mit antiepileptischer und verfahren zu deren herstellung
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
PT1192161E (pt) Cromeno¬4,3,2/de| isoquinolinas como ligandos potentes de receptores de dopamina
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
TH50541A (th) เกลือเมซีเลทไดไฮเดรทของ 5-(2-(4-(1,2-เบนไซโซไทอะโซล-3-อิล)-1-พิเพอราซินิล)เอทิล)-6-คลอโร-1,3-ไดไฮโดร-2h-อินโดล-2-โอน
TH22562B (th) เกลือเมซีเลทไดไฮเดรทของ 5-(2-(4-(1,2-เบนไซโซไทอะโซล-3-อิล)-1-พิเพอราซินิล)เอทิล)-6-คลอโร-1,3-ไดไฮโดร-2h-อินโดล-2-โอน
DE60308127D1 (de) Pharmazeutische Zusammentsetzung zur medizinischen Behandlung von gutartiger prostathyperplasie, dessen Vorbereitungsmethode und dessen therapeutische Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392676

Country of ref document: EP

REN Ceased due to non-payment of the annual fee